Data Support Neoadjuvant and Adjuvant Pembrolizumab in Resectable Melanoma
Source: Cancer Therapy Advisor, September 2022
The combination of neoadjuvant and adjuvant pembrolizumab appears more effective than adjuvant pembrolizumab alone for patients with resectable melanoma, according to a phase 2 study presented at ESMO Congress 2022.
“Compared to the same treatment given entirely in the adjuvant setting, neoadjuvant pembrolizumab followed by adjuvant pembrolizumab improves event-free survival in resectable melanoma,” said study presenter Sapna Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston.
“The use of neoadjuvant pembrolizumab did not increase adverse events in the perioperative period,” she added.